🎉 M&A multiples are live!
Check it out!

Public Comps and Valuation Multiples
for FemTech

Benchmark revenue and EBITDA valuation multiples for public comps like Jiangsu Bioperfectus, Curves Holdings Co., Neurocrine Biosciences, Veru and InMode.

Company	EV	EV/Revenue	EV/EBITDA
Hologic	$13.8B	3.4x	10.3x
Organon	$11.1B	1.7x	5.7x
Neurocrine Biosciences	$8.8B	3.6x	12.8x
Abbott India	$7.1B	9.4x	36.3x
InMode	$435M	1.1x	3.4x
Curves Holdings Co.	$385M	1.5x	6.6x
Jiangsu Bioperfectus	$290M	n/a	n/a
Elutia	$93.6M	3.5x	-7.3x
Veru	$56.7M	6.3x	n/a
Futura Medical	$33.7M	1.7x	6.2x
Applied BioCode	$33.4M	n/a	n/a
Dare Bioscience	$11.5M	23.9x	n/a
Atossa Therapeutics	$10.9M	n/a	n/a
Movano	-$2.0M	n/a	n/a
Context Therapeutics	-$17.5M	n/a	n/a
Olema Pharmaceuticals	-$155M	n/a	1.1x